☆ 4.6 Meeting Abstract

Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naive patients (pts) with EGFR mutant NSCLC

JOURNAL OF THORACIC ONCOLOGY (2016)

Journal

JOURNAL OF THORACIC ONCOLOGY

Volume 11, Issue 4, Pages S79-S79

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/S1556-0864(16)30171-X

Keywords

-

Categories

Oncology Respiratory System

Funding

MedImmune, the global biologics R&D arm of AstraZeneca

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA)

Deborah Smith, Kristy P. Robledo, Sonia Yip, Michelle M. Cummins, Peey-Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine Coward, Philip Beale, Geraldine Goss, Tarek Meniawy, Janine Lombard, Amanda B. Spurdle, John Andrews, Martin R. Stockler, Linda Mileshkin, Yoland Antill

Summary: Until recently, the outcome for women with advanced endometrial carcinoma has been poor. New immune therapies have improved outcomes for some women, but determining which women will respond is important. This study aimed to find markers to better predict response to immunotherapy. Tumor-associated inflammatory cells were found to have the strongest association with response. A novel algorithm using optimal cutoff points was able to identify non-responders with high sensitivity. Further validation is needed.

CANCERS (2023)

Add to Collection

Article Oncology

Tumor PD-L1 expression is associated with outcomes in stage 3 NSCLC patients treated with consolidation durvalumab

Khalid Jazieh, Mohamed Gad, Anas Saad, Wei Wei, Nathan A. Pennell

Summary: The study found that patients with tumor PD-L1 expression >50% had significantly longer progression-free survival and overall survival compared to those with lower expression. This suggests that the degree of tumor PD-L1 expression may play a role in predicting benefit from Durvalumab in these patients.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

Add to Collection

Article Immunology

Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance

Yujing Li, Haohua Jiang, Fangfei Qian, Ya Chen, Wensheng Zhou, Yanwei Zhang, Jun Lu, Yuqing Lou, Baohui Han, Wei Zhang

Summary: This study retrospectively investigated the outcomes of immune checkpoint inhibitor (ICI)-based treatments for EGFR-mutated NSCLC patients with PD-L1 TPS ≥ 50% after EGFR-TKI resistance. Results showed that ICI-based treatment, especially in combination with chemotherapy, provided better survival outcomes compared to classical chemotherapy.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Oncology

Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers

Laith Al-Showbaki, Michelle B. Nadler, Alexandra Desnoyers, Fahad A. Almugbel, David W. Cescon, Eitan Amir

Summary: Based on a network meta-analysis, pembrolizumab, nivolumab, and atezolizumab showed similar efficacy, with avelumab appearing less effective. Safety and tolerability were better with avelumab, but worse with atezolizumab and pembrolizumab.

JOURNAL OF CANCER (2021)

Add to Collection

Article Medicine, General & Internal

The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC A meta-analysis

Bo Lan, Yongfang Wang, Jingni Wu, Kai Wang, Pingli Wang

Summary: The expression of PD-L1 may predict a lower response rate to EGFR-TKI treatment, indicating a higher incidence of primary resistance. However, it does not correlate with progression-free survival or overall survival.

MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naive advanced EGFR-mutant non-small cell lung cancer patients

Kuo-Hsuan Hsu, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Yen-Hsiang Huang, Gee-Chen Chang

Summary: Strong expressions of PD-L1 in treatment naive advanced EGFR-mutant NSCLC patients were associated with poor prognoses in those undergoing treatment with osimertinib as first-line therapy.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Oncology

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer

Marina C. Garassino, Luis Paz-Ares, Rina Hui, Corinne Faivre-Finn, Alex Spira, David Planchard, Mustafa Ozguroglu, Davey Daniel, David Vicente, Shuji Murakami, Corey Langer, Suresh Senan, David Spigel, Anna Ryden, Yiduo Zhang, Cathy O'Brien, Phillip A. Dennis, Scott J. Antonia

Summary: This retrospective study investigated the impact of tumor PD-L1 expression and prior CRT-related variables on patient-reported outcomes in the PACIFIC trial. The findings indicate that neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy, with most PROs remaining stable across different subgroups.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD--L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol

Fiona Hegi-Johnson, Stacey E. Rudd, Christian Wichmann, Tim Akhurst, Peter Roselt, Jenny Trinh, Thomas John, Lisa Devereux, Paul S. Donnelly, Rod Hicks, Andrew M. Scott, Daniel Steinfort, Stephen Fox, Benjamin Blyth, Sagun Parakh, Gerard G. Hanna, Jason Callahan, Kate Burbury, Michael MacManus

Summary: This study aims to determine the feasibility of using 89Zr-durvalumab PET/CT to investigate PD-L1 expression in larger multicentre clinical trials. By recruiting patients and collecting data, researchers are trying to establish the viability of 89Zr-durvalumab PET/CT in larger scale clinical trials.

BMJ OPEN (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment

Cheng-Yu Chang, Yi-Chun Lai, Yu-Feng Wei, Chung-Yu Chen, Shih-Chieh Chang

Summary: Epidermal growth factor receptor (EGFR) mutations are most common in Eastern Asia and EGFR-tyrosine kinase inhibitors (TKIs) are recommended as first-line therapeutic options for non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations. The expression of programmed cell death-ligand 1 (PD-L1) in patients with metastatic NSCLC and EGFR mutations is not uncommon, but its influence on clinical outcomes with standard initial treatment seems to be insignificant.

ONCOTARGETS AND THERAPY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Small molecule TKI inhibitors affect the development of non-small cell carcinoma through HIPPO/YAP/PD-L1

Li Lei, Zhang Weidong

Summary: This study investigated the factors influencing the development of non-small cell lung cancer and the effects of small molecule inhibitors targeting the HIPPO/YAP/PD-L1 signaling pathway, providing a basis for tumor targeting therapy and immunotherapy.

CELLULAR AND MOLECULAR BIOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Comparison of PD-L1 Scores in Primary Kidney Tumors Versus Accompanying Venous Tumor Thrombi: Retrospective, Comparative, Monocentric Study in Treatment-Naive Patients

Mehrdad Mazdak, Rieke Ringlstetter, Pouriya Faraj Tabrizi, Meryem Akkoyun, Mathias Wolters, Jessica Schmitz, Jan Hinrich Braesen, Inga Peters, Markus Antonius Kuczyk, Hossein Tezval

Summary: This study investigated PD-L1 expression in 71 cases of PTs and VTT, with no significant differences found between the two. Factors such as age and gender were also not statistically proven to influence PD-L1 expression. These findings could have implications for future neoadjuvant immunotherapy options in aRCC with VTT.

ADVANCES IN THERAPY (2021)

Add to Collection

Article Oncology

Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naive metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study

Bo Xu, Huihui Cheng, Kunhong Li, Yukai Lv, Xianshang Zeng, Tao Liu, Weiguang Yu, Wenbo Guo

Summary: This retrospective review compared the efficacy and safety of atezolizumab plus carboplatin and nab-paclitaxel regimen versus carboplatin and nab-paclitaxel regimen for treatment-naive, metastatic nonsquamous PD-L1-positive NSCLC. The study found that ACN regimen had better overall survival and progression-free survival, but had more adverse events.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naive Patients with EGFRm plus NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

Hai-Yan Tu, Jifeng Feng, Meiqi Shi, Jun Zhao, Yuyan Wang, Jianhua Chang, Jialei Wang, Ying Cheng, Jing Zhu, Eng-Huat Tan, Kai Li, Yiping Zhang, Victor Lee, Cheng-Ta Yang, Wu-Chou Su, David Chi-Leung Lam, B. J. Srinivasa, Senthil Rajappa, Ching-Liang Ho, Kwok Chi Lam, Yi Hu, Shailesh Arjun Bondarde, Xiaoqing Liu, Yahui Tian, Zhiyi Xue, Agnieszka Cseh, Dennis Chin-Lun Huang, Caicun Zhou, Yi-Long Wu

Summary: The use of afatinib in Chinese patients with EGFRm+ NSCLC shows consistent safety and efficacy results compared to global studies. Dose reduction can improve treatment tolerability and clinical benefit.

TARGETED ONCOLOGY (2022)

Add to Collection

Article Oncology

Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor-a Danish cohort study

Julie Gabe Dissing, Maiken Parm Ulhoi, Boe Sandahl Sorensen, Peter Meldgaard

Summary: This study investigated the predictive potential of PD-L1 expression as a biomarker for treatment outcome in NSCLC patients with EGFR mutations. The results showed that PD-L1 expression levels did not significantly impact the duration of clinical benefit from tyrosine kinase treatment in the cohort of 111 Danish patients.

TRANSLATIONAL LUNG CANCER RESEARCH (2022)

Add to Collection

Article Oncology

The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors

Herdee Gloriane C. Luna, Marcelo Severino Imasa, Necy Juat, Katherine Hernandez, Treah May Sayo, Gloria Cristal-Luna, Sheena Marie Asur-Galang, Mirasol Bellengan, Kent John Duga, Bien Brian Buenaobra, Marvin I. De los Santos, Daniel Medina, Jamirah Samo, Venus Minerva Literal, Neil Andrew Bascos, Sullian Sy-Naval

Summary: The prognostic value of PD-L1 in EGFR-mutant NSCLC remains controversial, and the prognostic studies in Filipinos with EGFR-mutant NSCLC have not been explored. The results showed that PD-L1 positivity was associated with longer progression-free survival but had a contrasting influence on overall survival. PD-L1 and EGFR-sensitizing mutations were influenced by NSCLC subtypes, disease stage, and PD-1 expression.

TRANSLATIONAL LUNG CANCER RESEARCH (2023)

Add to Collection

Article Oncology

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients withEGFRmutation-positive locally advanced/metastatic non-small-cell lung cancer

Benjamin C. Creelan, Tammie C. Yeh, Sang-We Kim, Naoyuki Nogami, Dong-Wan Kim, Laura Q. M. Chow, Shintaro Kanda, Rosemary Taylor, Weifeng Tang, Mei Tang, Helen K. Angell, Martine P. Roudier, Marcelo Marotti, Don L. Gibbons

Summary: This study evaluated the safety and efficacy of Durvalumab and gefitinib in combination for TKI-naive patients with advanced EGFRm NSCLC. The results showed that this combination therapy had higher toxicity than using either agent alone, and did not significantly increase progression-free survival compared to historical controls.

BRITISH JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer

Bradford A. Perez, Sungjune Kim, Minhsuan Wang, Ahmad M. Karimi, Chase Powell, Jiannong Li, Thomas J. Dilling, Alberto Chiappori, Kujtim Latifi, Trevor Rose, Austin Lannon, Gretchen MacMillan, James Saller, G. Daniel Grass, Stephen Rosenberg, Jhanelle Gray, Eric Haura, Ben Creelan, Tawee Tanvetyanon, Andreas Saltos, Michael Shafique, Theresa A. Boyle, Michael J. Schell, Jose R. Conejo-Garcia, Scott J. Antonia

Summary: The study investigated the addition of ipilimumab and nivolumab after thoracic radiation therapy for patients with extensive stage small cell lung cancer, showing higher than expected overall survival rates. Increased CD3+CD8+ tumor infiltration was associated with favorable outcomes in terms of progression-free survival and overall survival.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Add to Collection

Letter Oncology

Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib

Misty D. Shields, J. Kevin Hicks, Theresa A. Boyle, Eric B. Haura, Benjamin C. Creelan

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

Benjamin C. Creelan, Chao Wang, Jamie K. Teer, Eric M. Toloza, Jiqiang Yao, Sungjune Kim, Ana M. Landin, John E. Mullinax, James J. Saller, Andreas N. Saltos, David R. Noyes, Leighann B. Montoya, Wesley Curry, Shari A. Pilon-Thomas, Alberto A. Chiappori, Tawee Tanvetyanon, Frederic J. Kaye, Zachary J. Thompson, Sean J. Yoder, Bin Fang, John M. Koomen, Amod A. Sarnaik, Dung-Tsa Chen, Jose R. Conejo-Garcia, Eric B. Haura, Scott J. Antonia

Summary: Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) in combination with nivolumab showed potential safety and clinical activity in patients with advanced non-small cell lung cancer, indicating a promising new treatment strategy for metastatic lung cancer.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer

Dung-Tsa Chen, Wenyaw Chan, Zachary J. Thompson, Ram Thapa, Amer A. Beg, Andreas N. Saltos, Alberto A. Chiappori, Jhanelle E. Gray, Eric B. Haura, Trevor A. Rose, Ben Creelan

Summary: This study identified the presence of lesion heterogeneity in cancer treatment, which is important for RECIST response classification. Evaluating this heterogeneity can aid in personalized treatment strategies and improve the accuracy of RECIST response classification.

PLOS ONE (2021)

Add to Collection

Article Oncology

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer

Alberto A. Chiappori, Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa, Margaret L. Barlow, Zhihua Chen, Dung Tsa Chen, Amer A. Beg, Theresa A. Boyle, Julio Castro, Liza Morgan, Erick Morris, Mehreteab Aregay, Felipe K. Hurtado, Luigi Manenti, Scott Antonia

Summary: This study evaluated the efficacy of taminadenant in patients with non-small cell lung cancer (NSCLC). The results showed that taminadenant, either as a single agent or in combination with spartalizumab, was well tolerated in advanced NSCLC patients and demonstrated clinical benefits regardless of prior immunotherapy or programmed cell death ligand-1 status.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors

Aung Naing, Alain P. Algazi, Gerald S. Falchook, Benjamin C. Creelan, John Powderly, Seth Rosen, Minal Barve, Niharika B. Mettu, Pierre L. Triozzi, John Hamm, Gongfu Zhou, Chris Walker, Zhiwan Dong, Manish R. Patel

Summary: This study evaluated the safety and efficacy of the combination therapy of the IDO1 inhibitor epacadostat and the PD-L1 monoclonal antibody durvalumab in patients with advanced solid tumors. The study findings showed that the combination therapy had common adverse events and low objective response rate, and a higher dose of epacadostat was needed for sufficient drug effect.

CANCER (2023)

Add to Collection

Article Oncology

Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

Casey L. Liveringhouse, Kujtim Latifi, Amalin G. Asous, Nghi B. Lam, Stephen A. Rosenberg, Thomas J. Dilling, Gretchen MacMillan, Alberto A. Chiappori, Eric B. Haura, Ben Creelan, Jhanelle E. Gray, Tawee Tanvetyanon, Michael R. Shafique, Andreas N. Saltos, Ashley A. Weiner, Jeffrey Clarke, Christopher R. Kelsey, Sungjune Kim, James J. Caudell, Trevor A. Rose, Jose R. Conejo-Garcia, Jiannong Li, Michael J. Schell, Scott J. Antonia, Bradford A. Perez

Summary: This multi-institution prospective trial was discontinued early due to unacceptable toxicity when using concurrent ipilimumab with chemoradiation therapy for patients with unresectable stage III non-small cell lung cancer. Despite toxicities, the median progression-free survival was 19.2 months, and the overall survival has not reached the median value yet.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Add to Collection

Meeting Abstract Oncology

Upfront Treatment With Osimertinib vs. Osimertinib and Radiotherapy for Patients With EGFR-Positive Non-Small Cell Lung Cancer Brain Metastases

A. E. Dohm, J. Tang, M. N. Mills, B. A. Perez, T. J. Robinson, B. Creelan, H. H. M. Yu, D. E. Oliver, K. A. Ahmed

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Add to Collection

Meeting Abstract Oncology

Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy Alone

A. E. Dohm, J. Tang, M. N. Mills, B. A. Perez, T. J. Robinson, B. Creelan, J. Gray, A. B. Etame, M. Vogelbaum, P. Forsyth, H. H. M. Yu, D. E. Oliver, K. A. Ahmed

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Add to Collection

Meeting Abstract Oncology

Prospective Phase I/II Study of Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC

C. Liveringhouse, N. B. Lam, S. A. Rosenberg, T. J. Dilling, G. Macmillan, A. Chiappori, E. B. Haura, B. Creelan, J. Gray, T. Tanvetyanon, M. Shafique, A. N. Saltos, A. A. Weiner, C. R. Kelsey, M. Schell, S. J. Antonia, B. A. Perez

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Add to Collection

Meeting Abstract Oncology

Sirt2 blockade promotes T cell metabolism and restores the anti-tumor immunity.

Imene Hamaidi, Lin Zhang, Nayoung Kim, Min Hsuan Wang, Cristina Iclozan, Bin Fang, Min Liu, John M. Koomen, Anders E. Berglund, Sean J. Yoder, Jiqiang Yao, Robert W. Engelman, Ben C. Creelan, Jose R. Conejo-Garcia, James J. Mule, Scott J. Antonia, Sungjune Kim

CANCER RESEARCH (2021)

Add to Collection

Meeting Abstract Oncology

Phase IIa study of marrow infiltrating lymphocytes (MILs), an adoptive T cell therapy, alone or in combination with nivolumab in non-small cell lung cancer (NSCLC).

Martin Edelman, Aaron Elliott Lisberg, Marianna Koczywas, Ben C. Creelan, Amanda Seiz, Eric Lutz, Lakshmi Rudraraju, Elizabeth DeOliveria, Monil Shah, Kim Noonan, Melissa Lynne Johnson

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

Understanding of cancer clinical trial data and statistical opportunities

Dung-Tsa Chen, Ben Creelan, Trevor Rose, Wenyaw Chan

CANCER RESEARCH (2020)

Add to Collection

Meeting Abstract Oncology

Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial

Ben Creelan, Chao Wang, Jamie Teer, Eric Toloza, John Mullinax, Jiqiang Yao, John Koomen, Sungjune Kim, Alberto Chiappori, James Saller, Leighann Montoya, Ana Marie Landin, Tawee Tanvetyanon, Bin Fang, Zachary Thompson, Xiaoping Yu, Andreas Saltos, Dung-Tsa Chen, Jose Conejo-Garcia, Eric Haura, Scott Antonia

CANCER RESEARCH (2020)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.